Scientific Program

Day 1 –  Friday, September 27

09:00-09:15

Opening/Welcome Remarks

David Metreveli, President of GHA

Hasmik Ghazinyan , President of ARASL

Session 1                                                

Updated Epidemiology and Burden of Disease

Moderators: Robert Gish (USA),  Hasmik Ghazinyan (Armenia), Maia Butsashvili (Georgia)

 

 

 

09:15-09:30

Prevalence of Hepatitis B and associated risk factors in Georgia

Ana Kasradze (Georgia)

09:30-09:45

HBV in Georgia –  Challenges and opportunities

David Metreveli (Georgia)

09:45-10:00

HBV in Armenia

Mher Davidyants (Armenia)

10:00-10:15

HBV in Azerbaijan

Yusif Alkhazov (Azerbaijan)

10:15-10:30

Problematic aspects in the diagnosis and treatment of chronic hepatitis B in Uzbekistan

Erkin Musabaev (Uzbekistan)

10:30-10:45

HBV/HCV co-infection among patients enrolled in HCV elimination program in Georgia

Maia Butsashvili (Georgia)

10:45-11:05

HBV Worldwide

Fransisco Averhoff (USA)

11:05-11:30

Panel Discussion

 
   

11:30-12:00

Coffee Break

 
 

 

 

Session 2

Natural History, Immunology and Diagnostics of HBV Infection

Moderators:  Francesco Negro  (Switzerland), Elza Vashakidze (Georgia), Mher Davidyants (Armenia)

 

 

 

12:00-12:20

Natural Course of HBV and predictors of disease progression

Robert Thimme (Germany)

12:20-12:30

Discussion

 

12:30-12:50

Viral replication and Immune response of HBV Infection

Robert Thimme (Germany)

12:50-13:00

Discussion

 

13:00-13:20

Current diagnostics and new markers of HBV infection 

Robert Gish (USA)

13:20-13:30

Discussion

 
   

13:30-14:30

Lunch

 
 

 

 

Session 3

Current and Promising Future Treatment of HBV

Moderators:  Robert Thimme (Germany), David Metreveli (Georgia),  Yusif Alkhazov (Azerbaijan)

 

 

 

14:30-14:50

Treatment indication  – differences between USA, Europe and Asia

Geoffrey Dusheiko (UK)

14:50-15:00

Discussion

 

15:00-15:20

Choice of treatment and predictors of outcome

George Lau (Hong Kong)

15:20-15:30

Discussion

 

15:30-15:50

Management of Normal ALT Subject

Shiv Sarin (India)

15:50-16:10

When to stop NUC treatment?

George Lau (Hong Kong)

16:10-16:20

Discussion

 

16:20-16:40

New promising approaches in HBV treatment

Calvin Pan (USA)

16:40-16:50

Discussion

 
   

16:50-17:15

Coffee Break

 
 

 

 

Session 4

Case presentations and discussions

Panel:  Calvin Pan (USA),

Geoffrey Dusheiko (UK),

Francesco Negro (Switzerland) 

 

 

 

17:15-18:30

Case 1, Case 2, Case 3

Mamuka zakalashvili (Georgia)

Jaba Zarkua (Georgia)

Violeta Sargsyan (Armenia)

Day 2 –  Saturday, September 28

Session 5

Special Groups (Part 1)   

Moderators: Calvin Pan (USA), Aregnaz Mkhitharyan (Armenia), Vahktang Kerashvili (Georgia)   

 

 

 

09:00-09:20

HBV Co-infections – HDV, HCV, HIV

Geoffrey Dusheiko (UK)

09:20-09:30

Discussion

 

09:30-09:50

HBV related cirrhosis

Geoffrey Dusheiko (UK)

09:50-10:00

Discussion

 

10:00-10:20

HCC in HBV patients

Robert Gish (USA)

10:20-10:30

Discussion

 

10:30-10:50

Hepatitis D and HCC

Francesco Negro (Switzerland)

10:50-11:00

Discussion

 
   

11:00-11:30

Coffee Break

 
 

 

 

Session 6

Special Groups (Part 2)

Moderators:  Geoffrey Dusheiko (UK), Irakli Rtskhiladze (Georgia), Violeta Sargsyan (Armenia)   

 

 

 

11:30-11:50

HBV reactivation under immunosuppression

Robert Gish (USA)

11:50-12:00

Discussion

 

12:00-12:20

HBV and chronic kidney disease

George Lau (Hong Kong)

12:20-12:30

Discussion

 

12:30-12:50

HBV in Pregnant women  

Calvin Pan (USA)

12:50-13:00

Discussion

 

13:00-13:20

HBV – ACLF

Hasmik Ghazinyan (Armenia)

13:20-13:30

Discussion

 
   

13:30-14:30

Lunch

 
 

 

 

Session 7

Case presentations and discussions

Panel:  Robert Gish (USA),

Robert Thimme (Germany),

George Lau (Hong Kong)

 

 

 

14:30-16:00

Case 1, Case 2, Case 3

Jaba Zarkua (Georgia)

Mamuka zakalashvili (Georgia)

Aregnazan Mkhitaryan (Armenia)

   

16:00-16:20

Coffee Break

 
 

 

 

Session 8

HBV Elimination – Expectation or Reality?

Moderators:  Fransisco Averhoff (USA), Amiran Gamkrelidze (Georgia), Gayane Melik-Andreasyan (Armenia)

 

 

 

16:20-16:40

HBV Elimination strategy

Antons Mozalevskis (Denmark)

16:40-17:00

Georgian experience in HCV elimination – is that a way towards HBV elimination?

Fransisco Averhoff (USA)

17:00-17:20

Are we ready to think about HBV elimination in Armenia?

Lilit Avetisyan (Armenia) 

17:20-17:40

Eliminating Hepatitis in Uzbekistan – Uzbekistan Hepatitis Elimination Pilot (UHEP)

Shakhlo Sadirova (Uzbekistan)

17:40-18:00

Panel Discussion

 

18:00-18:10

Summary and Closing Remarks

 

20:00 Gala Dinner

Close Menu